SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AGM Group Holdings, Inc. is a technology company, which engages in the provision of financial solutions. It focuses on the research and development of blockchain-oriented ASIC chip, production of encryption mining machines, and financial technology software services. Its products and services include technology hardware research and development, and assembling and sales of technology hardware. The company was founded by Zhen Tao Jiang and Wen Jie Tang on April 27, 2015 and is headquartered in Hong Kong.

AGM Group Holdings Inc - Ordinary Shares - Class A

AGMH is trending due to news of a completed subsidiary sale for $57.45 million, significantly exceeding its market cap, sparking community excitement and a potential short squeeze. Traders are actively discussing entry and exit points, with some eyeing price targets, while also pointing to the stock's volatility and potential for quick gains. The focus remains on AGMH's low float and potential for further upward movement amidst broader discussions of Chinese stocks and market momentum.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to increasing investor interest in nuclear energy, particularly its potential to power AI data centers. The community is actively debating whether the stock is experiencing a justified rally or forming a bubble, given the company's current pre-revenue status. Some traders point to a possible gamma squeeze and a high short float, while others highlight the company's innovative technology and government support.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

UPC is trending due to its low float and high cash per share, leading to community speculation about a potential squeeze. Some traders are comparing it to previous runners like $BREA and $AGMH, while others anticipate news related to crypto.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to news of a $300M private investment for a Solana-based digital asset treasury, drawing attention from investors like ARK Invest. Community discussions revolve around potential price targets and the possibility of a short squeeze, with some comparing it to other crypto treasury plays. The stock's low float and news-driven momentum contribute to its volatile price action and heightened interest.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc (QUBT) is experiencing increased interest, potentially driven by government initiatives and sector momentum, as mentioned in a recent Benzinga article. Community discussion revolves around the stock's breakout potential, with some targeting higher prices, while others express skepticism, citing past earnings misses and valuation concerns. Overall, the conversation highlights a mix of bullish sentiment and caution amid the broader excitement surrounding quantum computing stocks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as the stock hits new all-time highs, fueled by optimism around potential AI content licensing deals with major players like Google and OpenAI. The community is closely watching for a breakout, with some anticipating a continued climb towards higher price targets, while others express concerns about overvaluation and potential pullbacks. Sentiment is also influenced by broader discussions around the platform's content moderation and political leanings.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending as the stock experiences increased volume and positive price movement, leading to community discussions about potential short squeezes and future military deals. Some investors are speculating on news catalysts and technical breakouts, while others are comparing its market cap to competitors in the EVTOL sector. Overall, the community is buzzing with anticipation for continued upward momentum.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending amid community excitement and anticipation for potential contracts and partnerships, particularly related to AI-driven solutions. Community members are closely watching for news catalysts and discussing the stock's potential to reach higher price levels, drawing comparisons to other AI plays. Bullish sentiment is fueled by the company's focus on sectors like national security and infrastructure.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber ($WYFI) is trending as investors discuss its potential in the AI data center space following its recent IPO. Community members are pointing to the company's low float and potential connection to Tom Lee as catalysts, while also highlighting Bit Digital's ($BTBT) stake in WhiteFiber and the potential for strategic moves. The focus is on upcoming news and contracts related to WhiteFiber's AI infrastructure and data center capabilities.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull's stock is seeing increased discussion, with community members debating its potential for a squeeze and long-term growth, while others express concern about dilution and its performance relative to other financial apps. The stock's behavior around key options strike prices and potential catalysts like rate cuts or Chinese investment are also hot topics. Overall, the sentiment appears mixed as traders weigh the potential upside against perceived risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences Corp. (AVXL) on Tuesday announced that its experimental Alzheimer’s drug demonstrated cognitive stabilization in patients with early Alzheimer’s disease in a study.After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine in a precision medicine population demonstrated barely detectable cognitive decline on all standard scales for measuring cognitive decline, comparable to the minimal decline in pre-dementia aging adults.Shares of the company rose 2% on Tuesday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-announces-oral-blarcamesine-cognitive-resilience-results-approximating-normal-a">said</a> that the drug caused about an 84.7% reduction in cognitive decline as compared to placebo on a standardized neuropsychological test used in Alzheimer's disease research to measure cognitive function.“Today’s new clinical efficacy data update from our Phase IIb/III trial is critical, as it adds contemporary context to Precision Medicine data showing strong protection from Alzheimer’s disease with an oral once-daily potential solution with the aim to alleviate significant medical and economic burden,” said Juan Carlos Lopez-Talavera, Head of Research and Development of Anavex.Anavex will continue to evaluate trial data, which will be published and presented at international conferences, the company said.Anavex is also studying Blarcamesine, its lead candidate, in dementia caused by Parkinson's disease, a neurodegenerative brain condition, and in patients with Rett syndrome, a rare genetic neurological and developmental disorder that affects the way the brain develops.AVXL stock is down 12% this year but up approximately 84% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-1.5-million-vehicles-in-us/chwKduPRdte">Ford Draws Retail Investor Concerns After It Recalls Nearly 1.5M Vehicles In US Over Rear View Camera Display Issues</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study

After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 

Equity

After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 


Anavex Life Sciences slipped in after-hours trading on Monday after the company said it plans to raise&nbsp;as much as $300 million by selling shares.The stock closed at $11.48 on Monday, up 3.3% for the day, before slipping 1% to $11.37 in after-hours trading.The stock offering comes on the heels of its latest quarterly results,&nbsp;which showed net loss was $11.2 million, or $0.13 a share, compared with a loss of $10.5 million in the same period last year.&nbsp;The company had $115.8 million in cash at the end of March and said that it would fund the company for about four years.In April, Anavex disclosed an update on the long-term data on its Alzheimer’s candidate, blarcamesine. According to new data released, the drug slowed cognitive decline in early-stage Alzheimer’s patients over&nbsp;four years.&nbsp;The results were disclosed at the AD/PD 2025 conference, and they hint that the treatment may have a disease-modifying effect if started early and taken continuously.The drug has also been well tolerated. No&nbsp;significant safety issues were reported, and dizziness, the most common side effect, was reduced by tweaking the dose schedule.Anavex has also wrapped up enrollment for a mid-stage trial of its schizophrenia drug, Anavex 3-71, with results expected in the second half of the year.&nbsp;Separately, 74 patients remain on long-term blarcamesine therapy through a Compassionate Use Program, with some having taken the drug daily for over nine years.On Stocktwits, retail sentiment for Anavex was ‘extremely bullish’ amid ‘high’ message volume.One user viewed the shelf registration as a bullish signal, suggesting that Anavex may be positioning itself for a potential EMA approval.&nbsp;They speculated the filing could be tied to plans for standalone distribution or as a strategic move to strengthen the company’s hand in partnership talks, calling it “nothing but good news” for long-term holders.<stembedurl>https://stocktwits.com/PartyNaked/message/620947957</stembedurl>Another user said that the S-3 filing doesn’t mean an immediate offering, but rather gives the company flexibility to raise funds if needed, particularly after a major catalyst like an EMA decision.&nbsp;They called the move smart and standard for biotech firms, arguing it allows Anavex to act quickly if the stock jumps post-approval and strengthens its negotiating position with potential partners.<stembedurl>https://stocktwits.com/kay91667/message/620942567</stembedurl>Anavex’s stock has declined 5.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avanex Life Sciences (AVXL) said it plans to raise up to $300 million by selling shares. (Photo credit: Getty Images)

Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It’s A ‘Smart’ Move 

The after-hours move followed Anavex’s recent completion of enrollment for a mid-stage schizophrenia trial, with top-line results expected later this year. 

Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging  Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday. The stocks trending the most on the Stocktwits platform include Webull, SharpLink, Anavex Life Sciences, BigBear.ai, and Oscar Health.1. Webull Corp. (BULL)<img src="https://news.stocktwits-cdn.com/BULL_png_3a86d4a0fc.webp" alt="BULL.png">2. SharpLink Gaming Ltd. (SBET)<img src="https://news.stocktwits-cdn.com/SBET_png_ddf51dbef1.webp" alt="SBET.png">3. Anavex Life Sciences Corp. (AVXL)<img src="https://news.stocktwits-cdn.com/AVXL_png_b962881047.webp" alt="AVXL.png">4. BigBear.ai Holdings Inc. (BBAI)<img src="https://news.stocktwits-cdn.com/BBAI_png_3156927dd7.webp" alt="BBAI.png">5. Oscar Health Inc. (OSCR)<img src="https://news.stocktwits-cdn.com/OSCR_png_e8f637dd66.webp" alt="OSCR.png">Disclaimer: Stocktwits' "Why It's Trending" summary is AI-generated and may contain errors.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-us-make-fortune-if-big-beautiful-bill-is-passed-but-house-republicans-could-sink-it/chF0ot3RTyE">Trump Says US Will ‘Make A Fortune’ If The Big Beautiful Bill Is Passed, But House Republicans Could Sink It</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 06, 2024 in New York City as the market opened after the worst crash since 2022

Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday.

Lightning Round: Sell Viking Therapeutics, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, Transocean, and DuPont...

Anavex Life Sciences Corp., a small-cap biotech specializing in neurodegenerative and neurodevelopmental diseases, emerged as the top pick among retail investors in a recent Stocktwits poll.&nbsp;Nearly 45% of respondents believe Anavex will outperform in the first quarter of 2025, compared to 33% for Novavax and 9% for Rigel Pharmaceuticals.<stembedurl>https://stocktwits.com/StocktwitsPolls/message/599783274</stembedurl>Alzheimer’s Therapy MomentumAnavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73), whose European Marketing Authorization Application was&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/avxl-stock-rises-on-q4-results-ema-nod-for-blarcamesine/cJazDmdRj5">accepted</a> last month.&nbsp;Promising trial results showed three years of continuous blarcamesine treatment significantly reduced clinical decline in early Alzheimer’s patients, with no safety issues reported.&nbsp;That positions the drug as a potential breakthrough, especially as interest in Alzheimer’s therapies intensifies following recent setbacks for rivals like Cassava Sciences.The company’s stock surged over 76% in 2024 but is down 6% year-to-date, with a high short interest of 24.5% as per Koyfin data.&nbsp;Anavex reported $132.2 million in cash reserves as of Sept. 30, 2024, and projects a four-year cash runway at its current burn rate.Vaccine Maker Eyes RecoveryNovavax has maintained momentum after a 68% gain in 2024, with shares up nearly 6% this year.&nbsp;The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvax-stock-is-undervalued-say-retail-investors/chGWtkSRZy">recovered</a> from an FDA clinical hold on its COVID-19 and flu combination vaccine late last year, thanks to a $50 million milestone payment under its Sanofi partnership and increasing hopes for a bird flu vaccine.&nbsp;Novavax holds the largest market cap among the three at $1.38 billion. It has $909.5 million in cash and a manageable debt load of $262 million, which many retail investors see as an advantage.&nbsp;It also has a high short interest of 24.5%.Under-The-Radar Bet?Rigel Pharmaceuticals focuses on autoimmune and hematologic diseases. The company recently received orphan drug designation for R289, a treatment for lower-risk myelodysplastic syndromes.&nbsp;A growing portfolio of approved therapies, such as TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for acute myeloid leukemia has also boosted retail sentiment.On Monday, the company said it expects fourth-quarter revenue of $57.6 million, up 61% year-over-year and above a Wall Street estimate of $47.4 million. It also projected 2025 revenue of $200-$210 million, better than an expected $193.5 million.Rigel’s stock rose 15% in 2024 and remained nearly flat in 2025. As of Dec. 31, 2024, it had estimated cash reserves of $77.3 million.&nbsp;Rigel’s short interest is relatively low at 3.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Anavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73). | Image source: Getty Images 

Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

Anavex Life Sciences Corp. shares rocketed over 27% on Monday, hitting their highest levels since February 2023, fueled by a mix of positive earnings results and regulatory progress in Europe.The biopharma company, focused on neurodegenerative and neurodevelopmental diseases, reported a fiscal fourth-quarter loss of $11.6 million, or an adjusted $0.14 per share, compared to a loss of $10.1 million in the year-ago period.&nbsp;While research and development (R&amp;D) and overhead costs rose, the per-share loss was narrower than the FactSet consensus estimate of $0.16.Anavex also highlighted a strong cash position, with $132.2 million in reserves, which the company says will provide a four-year runway at current burn rates.Creating more buzz was news that the European Medicines Agency (EMA) accepted the Marketing Authorization Application for blarcamesine (ANAVEX 2-73), an investigational oral drug for Alzheimer’s disease.&nbsp;Anavex’s Head of R&amp;D, Juan Carlos Lopez-Talavera, said: "The EMA filing acceptance for blarcamesine to review the Marketing Authorization Application potentially brings us a step closer offering broader patient access to a new treatment option in Europe, and we look forward to continued engagement with the EMA.”CEO Christoper Missling said, "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains deeply committed to executing on our momentum.”<figure class="image"><img style="aspect-ratio:1326/1056;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_poll_sentiment_and_message_volume_Dec_24_fe40cd4f12.png" alt="AVXL poll sentiment and message volume Dec 24.png" width="1326" height="1056"><figcaption>AVXL poll, sentiment and message volume on Dec 24 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits celebrated the news, with sentiment shifting sharply to ‘bullish’ from ‘neutral.’&nbsp;Many hailed the EMA filing as a significant milestone, with one user claiming very high approval rates by the European regulator for “accepted drug candidates in 2024 that aren't withdrawn.”<stembedurl>https://stocktwits.com/Guzzi62/message/597573043</stembedurl><stembedurl>https://stocktwits.com/PhillipHerass/message/597572113</stembedurl><stembedurl>https://stocktwits.com/Logic102/message/597572650</stembedurl>According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10499418/">study</a> published last year in the Clinical and Translational Science, an official journal of the American Society for Clinical Pharmacology and Therapeutics, the EMA was found to have the highest approval rate (93.8%) for non-oncology products when compared with Swiss and U.S. regulators. The data analyzed decisions between 2009 and 2018 on new active substances.The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh">reported</a> disappointing results for its candidate simufilam last month.&nbsp;D. Boral Capital had noted Anavex’s neuroprotective mechanism could position blarcamesine as a superior option, reiterating a ‘Buy’ rating with a $46 price target.Anavex shares are now up 88% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

EMA European Medicines Agency at Canary Wharf on 5th November 2024 in London, United Kingdom. (photo by Mike Kemp/In Pictures via Getty Images)

Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed

The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.

What To Expect in the Markets This Week

Coming up: Shortened market hours around the Christmas holiday, consumer confidence, new home sales, initial jobless claimsGetty ImagesKey TakeawaysMarkets are closed Wednesday for Christmas.On...

This Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),&nbsp; AI (The Theme of the Year)&nbsp;WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.Here's a list of today's most important names:1. Cassava Sciences (NASDAQ: SAVA)Background: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.The News: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.What It Means: This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.Stock Reaction: Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.&nbsp;2. Poseida Therapeutics (NASDAQ: PSTX)Background: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.The News: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.What It Means: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.Stock Reaction: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.&nbsp;3. KULR Technology Group (NYSE: KULR)Background: KULR specializes in thermal management technologies for energy storage and aerospace.The News: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.What It Means: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.Stock Reaction: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.&nbsp;4. POET Technologies (NASDAQ: POET)Background: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.The News: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.What It Means: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.Stock Reaction: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.&nbsp;5. SurgePays (NASDAQ: SURG)Background: SurgePays provides financial services and prepaid wireless solutions for underserved markets.The News:&nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.What It Means: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.Stock Reaction: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.&nbsp;6. TOYO Ventures Holdings (NASDAQ: TOYO)Background: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.The News: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.What It Means: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..Stock Reaction: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.&nbsp;&nbsp;7. Anavex Life Sciences (NASDAQ: AVXL)Background:&nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.The News:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.What It Means:&nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.Stock Reaction: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.&nbsp;&nbsp;Be The First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST&nbsp;SpaceMobile (NASDAQ: ASTS) which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WealthyVC">Follow us on Twitter</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/wealthyventurecapital/">Follow us on Instagram</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN">Follow us on Facebook</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.14	--	--	N/A
Q3 '25	-$0.14	-$0.16	-12.41%	MISSED
Q2 '25	-$0.15	-$0.13	13.33%	BEAT
Q1 '25	-$0.17	-$0.14	17.65%	BEAT
Q4 '24	-$0.16	-$0.14	14.29%	BEAT

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AVXL News

AVXL Anavex Life Sciences Corp